Noncoding RNAs Associated with PPARs in Etiology of MAFLD as a Novel Approach for Therapeutics Targets
Open Access
- 17 September 2022
- journal article
- research article
- Published by Wiley in PPAR Research
- Vol. 2022, 1-13
Abstract
Noncoding RNAs Associated with PPARs in Etiology of MAFLD as a Novel Approach for Therapeutics Targets: Background. Metabolic associated fatty liver disease (MAFLD) is a complex disease that results from the accumulation of fat in the liver. MAFLD is directly associated with obesity, insulin resistance, diabetes, and metabolic syndrome. PPARγ ligands, including pioglitazone, are also used in the management of this disease. Noncoding RNAs play a critical role in various diseases such as diabetes, obesity, and liver diseases including MAFLD. However, there is no adequate knowledge about the translation of using these ncRNAs to the clinics, particularly in MAFLD conditions. The aim of this study was to identify ncRNAs in the etiology of MAFLD as a novel approach to the therapeutic targets. Methods. We collected human and mouse MAFLD gene expression datasets available in GEO. We performed pathway enrichment analysis of total mRNAs based on KEGG repository data to screen the most potential pathways in the liver of MAFLD human subjects and mice model, and analyzed pathway interconnections via ClueGO. Finally, we screened disease causality of the MAFLD ncRNAs, which were associated with PPARs, and then discussed the role of revealed ncRNAs in PPAR signaling and MAFLD. Results. We found 127 ncRNAs in MAFLD which 25 out of them were strongly validated before for regulation of PPARs. With a polypharmacology approach, we screened 51 ncRNAs which were causal to a subset of diseases related to MAFLD. Conclusion. This study revealed a subset of ncRNAs that could help in more clear and guided designation of preclinical and clinical studies to verify the therapeutic application of the revealed ncRNAs by manipulating the PPARs molecular mechanism in MAFLD.Keywords
This publication has 109 references indexed in Scilit:
- Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesisGut, 2014
- NAFLD, NASH and liver cancerNature Reviews Gastroenterology & Hepatology, 2013
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisHepatology, 2013
- Management of Non-alcoholic Fatty Liver Disease and SteatohepatitisJournal of Clinical and Experimental Hepatology, 2012
- The interaction of hepatic lipid and glucose metabolism in liver diseasesJournal of Hepatology, 2012
- Nonalcoholic fatty liver disease and nonalcoholic steatohepatitisHepatology, 2008
- Adipocytokines and liver diseaseJournal of Gastroenterology, 2008
- Pathology of Nonalcoholic Fatty Liver DiseaseAmerican Journal of Clinical Pathology, 2007
- Peroxisome Proliferator-activated Receptor α (PPARα) Influences Substrate Utilization for Hepatic Glucose ProductionJournal of Biological Chemistry, 2002
- Defect in Peroxisome Proliferator-activated Receptor α-inducible Fatty Acid Oxidation Determines the Severity of Hepatic Steatosis in Response to FastingJournal of Biological Chemistry, 2000